Showing results (121-130 of 169) with videos related to
Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Li Wei, Xiaosheng Fang, et al.Oncotarget|November 18, 2015
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphomaQing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, et al.Hematological Oncology|June 22, 2025
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)Annarita Conconi, Andrea Janikova, Barbara Vannata, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaChi Young Ok, Jiayu Chen, Zijun Y Xu-Monette, et al.Blood|July 5, 2022
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapseChiara Rusconi, Chan Y Cheah, Toby A Eyre, et al.Aging|December 13, 2016
RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphomaMingzhi Zhang, Zijun Y Xu-Monette, Ling Li, et al.Cell Reports. Medicine|January 19, 2024
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donorsFrancesca Pettinella, Barbara Mariotti, Chiara Lattanzi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2023
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCLZijun Y Xu-Monette, Yong Li, Thomas Snyder, et al.Journal of Hematology & Oncology|November 5, 2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Mingzhi Zhang, Zijun Y Xu-Monette, et al.Blood|August 16, 2015
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, et al.Pageof 17